Steven Cohen Cidara Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,250,000 shares of CDTX stock, worth $14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,250,000
Previous 1,250,000
-0.0%
Holding current value
$14 Million
Previous $987,000
16.51%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CDTX
# of Institutions
53Shares Held
22.2MCall Options Held
2.7KPut Options Held
100-
Bvf Inc San Francisco, CA6.86MShares$76.9 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$37.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.55MShares$28.6 Million0.0% of portfolio
-
Alethea Capital Management, LLC San Diego, CA1.6MShares$17.9 Million1.21% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA1.13MShares$12.7 Million0.37% of portfolio
About Cidara Therapeutics, Inc.
- Ticker CDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,075,696
- Market Cap $786M
- Description
- Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...